Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II randomized double-blind placebo-controlled dose-escalation and dose-expansion study of SRSD216 in subjects with elevated lipoprotein(a)
CTR20251063Phase 2Active
- Sponsor
- Jingyin Biopharma
- Start
- Apr 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SRSD216 in hyperlipoproteinemia, sponsored by Jingyin Biopharma. Started Apr 2025; status: active.
02
Drugs
SRSD216
03
Conditions
hyperlipoproteinemia
Beyond the preview
Go deeper on CTR20251063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251063.